A new chemotherapeutic for liver cancer

What is liver cancer?

The liver is the football-sized organ in the upper right area of the belly. Symptoms are uncommon in the early stages of liver cancer. Later, symptoms may include weight loss, belly pain, vomiting, and yellowed skin. Treatments vary but may include removal of part of the liver, transplant, chemotherapy, and in some cases radiation. 

What causes liver cancer?

Primary liver cancer (hepatocellular carcinoma) tends to occur in livers damaged by birth defects, alcohol abuse, or chronic infection with diseases such as hepatitis B and C, hemochromatosis (a hereditary disease associated with too much iron in the liver), and cirrhosis. 

Who is most likely to get liver cancer?

Age: In the United States, the average age at onset of liver cancer is 63 years.Gender: Men are more likely to develop liver cancer than women, by a ratio of 2 to 1.Race and ethnicity: In the United States, liver cancer rates are highest in Asian Americans and Pacific Islanders. White Americans have the lowest risk for liver cancer. Chronic infection with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) is the most common liver cancer risk factor. These infections lead to cirrhosis of the liver (see below). Both hepatitis B and C viruses can spread from person to person through sharing of contaminated needles (such as in drug use), unprotected sex, or childbirth. They can also be passed on through blood transfusion; however, this risk has been minimized in the United States since the start of blood testing for these viruses.

What are the symptoms of liver cancer?

Symptoms are uncommon in the early stages of liver cancer. Later, symptoms may include weight loss, belly pain, vomiting, and yellowed skin.  

Current Standard of care


High-energy x-rays or other

particles destroy cancer cells


Tryosine kinase inhibitor

antineoplastic agent, Nexavar


Hepatectomy or liver transplantation


Radiofrequency ablation (RFA) and

microwave therapy


Percutaneous ethanol injection

UTTROSIDE-B Chemotherapeutic

P Uttroside-B appears to affect phosphorylated JNK (pro survival signaling) and capcase activity (apoptosis inliver cancer)

§A natural compound
§Fractionated Saponin derived from S. nigrum
§Small molecule
§Steroid Glycoside

Uttroside B increases the cytotoxicity of a variety of liver cancer cell types

Up to 10x more potent than Sorafenib in pre clinical studies

Cytotoxicity specific to cancerous liver cells

Provisional patent filed

IND Ready Q1 2018

Sorafenib Tosylate (Nexavar) is the only FDA- approved marketed drug for the treatment of liver cancer. 2016 sales exceeded  $ 1 B.

Copyright © 2017 Q BioMed, Inc. All Rights Reserved




366 Madison Ave, 3rd Floor
New York, NY 10022 USA
P: +1 888 357 2435
E: info@qbiomed.com